Recognify Life News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recognify life. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recognify Life Today - Breaking & Trending Today

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial ....

New York , United States , City Of , United Kingdom , Brandtj Hopkins , Camilla Dormer , Clin Psychopharmacol , Richard Se Keefe , Matthew Pando , Life Sciences Nasdaq , Founder Of Recognify Life Sciences , Recognify Life Sciences , Exchange Commission , Assessment Inc , Treatment Research To Improve Cognition In Schizophrenia , Life Sciences , Duke University , Cognitive Impairment Associated , Brief Assessment , Symbol Coding Test , Symbol Coding , Hopkins Verbal Learning Task , Treatment Research , Improve Cognition , Consensus Cognitive Battery , Florian Brand ,

Schizophrenia Pipeline: Analysis of 90+ key pipeline therapies, 90+ key pharma competitors, unmet needs, and opportunities

Over
90+ Schizophrenia pipeline therapies are under different stages of development and their expected approval in the Schizophrenia market shall uplift the market revenue significantly.
Out of emerging therapies,
AVP-786 is in Phase II/III stage of trials. Similarly,
MK-8189 is undergoing Phase II developmental phase for Schizophrenia.
Schizophrenia pipeline therapies in the early stages of development include
CAD-9303, and
In December 2020, FDA assigns PDUFA action date of (01/06/2021) for
ALKS 3831 for Schizophrenia and Bipolar disorders.
In June 2020, Neurocrine Biosciences and Takeda entered into a strategic collaboration agreement to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia. ....

United States , Neurocrine Biosciences , Los Angeles , Doria Risperidone , Minerva Neurosciences , Sunovion Pharmaceuticals , Avanir Pharmaceuticals , Teva Pharmaceutical , Newron Pharmaceuticals , Boehringer Ingelheim , Recognify Life Sciences , Acadia Pharmaceuticals , Syneurx International , Rovi Pharmaceuticals Laboratories , Karuna Pharmaceuticals , Route Of Administration , Bioxcel Therapeutics , Schizophrenia Pipeline Insights , Schizophrenia Pipeline Analysis , Schizophrenia Pipeline , Acutely Psychotic Subjects , Rovi Pharmaceuticals , Pipeline Therapies , Recognify Life , Cell Therapy , Delveinsight Business Research Llp ,